MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer

Abstract

A tumor-targeted HDR-BT salvage approach achieved favorable cancer control outcomes. While a fBT was associated with less toxicity, it may be best suited to a subgroup with lower PSA at later recurrence. Tumor targeted dose escalation may be warranted.